Summary
BeOne Medicines Ltd. (ONC) has filed an 8-K report detailing a significant regulatory event concerning its drug tislelizumab. On December 30, 2022, BeiGene, Ltd. announced that the China National Medical Products Administration's Center for Drug Evaluation has accepted a supplemental biologics license application for tislelizumab. This submission targets the first-line unresectable or metastatic hepatocellular carcinoma patient population in China.
Key Highlights
- 1BeiGene's supplemental biologics license application for tislelizumab has been accepted by China's NMPA.
- 2The application is for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (liver cancer).
- 3This acceptance represents a key step in the regulatory approval process for tislelizumab in a significant indication within China.
- 4Tislelizumab is a PD-1 inhibitor, a class of drugs known for its efficacy in various cancer treatments.
- 5The filing incorporates a press release from BeiGene dated December 30, 2022, providing further details on this event.